Strategies for Organic Drug Synthesis and Design

Your Blueprint for Successful Drug Synthesis and Design
Guiding readers through tested–and–proven strategies for designing and conducting drug synthesis, this Second Edition features the latest developments in the field, including new examples of drug synthesis from major pharmaceutical companies. Examples are selected from the multivolume work, titled The Organic Chemistry of Drug Synthesis. This new, expanded edition focuses on the organic chemistry used for drug preparation. Drugs have been selected based on the illustrative value of the chemistry used for their synthesis. Structures in chemical schemes have been carefully drawn to clarify individual reactions.
Brief discussions of medicinal chemistry provide readers with a snapshot of the activity and the mechanism of action of various drugs. Salient principles of drug action are presented in capsule form at appropriate points. In addition, the claimed therapeutic effects of each pharmaceutical agent are noted along with the discussion of its preparation.
Strategies for Organic Drug Synthesis and Design has been updated with a host of new drugs, including drugs that address new therapeutic areas and drugs developed with the use of novel chemistry. These include:
Tubulin Inhibitors (Taltobulin)
Antimalarial arteflene
Neuraminidase Antivirals (Zanamavir, Oseltamavir, and Peramavir)
COX–2 Inhibitor NSAIDs (Celecoxib, Cimicoxib, and Valdecoxib)
Written by an experienced and successful author and pharmaceutical scientist, this book meets the needs of the growing community of researchers in pharmaceutical R&D as well as medical professionals who need to understand the design and synthesis of pharmaceutical agents. It is also recommended as a graduate–level medicinal chemistry textbook.

Spis treści:
Preface
1. PROSTAGLANDINS, PEPTIDOMIMETIC COMPOUNDS, AND RETINOIDS.
1.1 Prostaglan dnis.
1.2 Peptidonimetic Compounds.
1.3 Retinoids.
1.4 A Miscellaneous Drug.
References.
2. DRUG BASED ON A SUBSTITUTED BENZENE RING
2.1 Arylethanolamines.
2.2 Aryloxypropanolamines.
2.3 Arylsulfonic Acid Derivatives.
2.4 Arylacetic and Arylpropionic Acids.
3. INDENES, NAPHTHALENES AND OTHER POLYCYCLIC AROMATIC COMPOUNDS
3.1 Indenes.
3.2 Naphthalenes.
3.3 Partly Reduced Naphthalenes.
3.4 Tricyclic Compounds.
References.
4. STEROIDS; PART 1: ESTRANES, GONANES, AND ANDROSTANES
4.1 Introduction.
4.2 Steroid Starting Materials.
4.3 Estranes.
4.4 Gonanes, the 19–nor Steroids.
4.5 Androstanes.
References.
5. STEROIDS; PART 2: COMPOUNDS RELATED TO PROGESTERONE, CORTISONE, AND CHOLESTEROL.
5.1 Introduction.
5.2 Progestins.
5.3 Corticosteroids.
5.4 Compounds Derived from Cholesterol.
References.
6. NONSTEROIDAL SEX HORMONES AND THEIR ANTAGONISTS
6.1 Introduction.
6.2 Estrogens.
References.
7. OPIOID ANAlGESICS
7.1 Introduction
7.2 Drugs Derived from Morphine.
7.3 Compounds Prepared from Thebaine.
7.4 Morphinans.
7.5 Benzomorphans.
7.6 Analgesics Based on Nonfused Piperidines.
References.
8. DRUGS BASED ON FIVE–MEMBERED HETEROCYCLES
8.1 Introduction.
8.2 Rings that Contain One Heteroatom.
8.3 Rings that Contain Two Heteroatoms.
8.4 Rings that Contains Three or More Heteroatoms.
References.
9. DRUGS BASED ON SIX–MEMBERED HETEROCYCLES.
9.1 Rings that Contain One Heteroatom.
9.2 Rings that Contain Two Heteroatoms.
9.3 Rings Containing Three Heteroatoms: The Triazines.
References.
10. FIVE–MEMBERED HETEROCYCLES FUSED TO A BENZENE RING.
10.1 Compounds that Contain One Heteroatom.
10.2 Compounds that Contain Two Heteroatoms.
10.3 Compounds that Contain Three Heteroatoms.
References.
11. SIX–MEMBERED HETEROCYCLES FUSED TO A BENZENE RING
11.1 Compounds that Contain One Heteroatom.
11.2 Compounds that Contain Two Heteroatoms.
11.3 Compounds that Contain Three Heteroatoms.
References.
12. SEVEN–MEMBERED HETEROCYCLIC FUSED TO BENZENE.
12.1 Compounds with a Single Heterocyclic Atom.
12.2 Compounds with Two Heteroatoms.
References.
13. HETEROCYLES FUSED TO TWO AROMATIC RINGS
13.1 Compounds Containing a Single Heteroatom.
13.2 Compounds Containing Two Heteroatoms.
13.3 Pyridine–Based Fused Tricyclic Compounds.
References.
14. BETA LACTAM ANTIBIOTICS
14.1 Penicillins.
14.2 Cephalosporins.
14.3 Monobactams.
References.
15. HETEROCYCLES FUSED TO OTHER HETEROCYCLIC RINGS.
15.1 Two Fused Five–Membered Rings.
15.2 Five–Membered Heterocycles Fused to Six–Membered Rings.
15.3 Two Fused Six–Membered Rings.
15.4 Heterodiazepines.
15.5 Heterocyclic Compounds with Three or More Rings.
References.
Subject Index.
Reaction Index.
Cross Index of Biological Activities.

Nota biograficzna:
Daniel Lednicer, PhD, is the acclaimed author of several books on drug synthesis and discovery. His career has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. He has also served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute.

Okładka tylna:
Your Blueprint for Successful Drug Synthesis and Design
Guiding readers through tested–and–proven strategies for designing and conducting drug synthesis, this Second Edition features the latest developments in the field, including new examples of drug synthesis from major phar maceutical companies. Examples are selected from the multivolume work, titled The Organic Chemistry of Drug Synthesis. This new, expanded edition focuses on the organic chemistry used for drug preparation. Drugs have been selected based on the illustrative value of the chemistry used for their synthesis. Structures in chemical schemes have been carefully drawn to clarify individual reactions.
Brief discussions of medicinal chemistry provide readers with a snapshot of the activity and the mechanism of action of various drugs. Salient principles of drug action are presented in capsule form at appropriate points. In addition, the claimed therapeutic effects of each pharmaceutical agent are noted along with the discussion of its preparation.
Strategies for Organic Drug Synthesis and Design has been updated with a host of new drugs, including drugs that address new therapeutic areas and drugs developed with the use of novel chemistry. These include:
Tubulin Inhibitors (Taltobulin)
Antimalarial arteflene
Neuraminidase Antivirals (Zanamavir, Oseltamavir, and Peramavir)
COX–2 Inhibitor NSAIDs (Celecoxib, Cimicoxib, and Valdecoxib)
Written by an experienced and successful author and pharmaceutical scientist, this book meets the needs of the growing community of researchers in pharmaceutical R&D as well as medical professionals who need to understand the design and synthesis of pharmaceutical agents. It is also recommended as a graduate–level medicinal chemistry textbook.